SOLV (SOLV)
Quantitative Summary
DeterministicFinancial health is average: Piotroski 6/9, Altman Z 2.0. Beneish M-Score of -2.08 exceeds the -2.22 academic threshold — earnings quality may warrant further review.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe equity economics display a compelling divergence between capital efficiency and growth velocity. A 14.6% ROIC suggests the firm generates returns above typical cost of capital, while the DuPont decomposition reveals that an 18.7% net margin is the primary engine driving a 30.8% ROE; this profitability is supported by moderate leverage (2.83x) and modest asset turnover (0.58x). Quality metrics reinforce this operational strength with a Piotroski F-Score of 6/9, indicating solid fundamentals despite recent stagnation in revenue growth at just 0.9% year-over-year. The Beneish M-Score of -2.08 further signals low earnings manipulation risk, suggesting the high margins are likely sustainable rather than accounting artifacts.
Valuation metrics present a significant discount relative to historical norms and peer averages implied by such robust profitability ratios. Trading at a 7.1x P/E multiple while maintaining nearly double-digit ROE is anomalous for a quality compounder, often implying the market has priced in persistent growth failure or sector-specific headwinds not fully captured in current earnings. A discounted cash flow analysis would likely highlight how the low implied forward growth rate suppresses fair value despite strong margin expansion and efficient capital deployment. The disconnect between high-quality fundamentals and depressed multiples creates a scenario where future catalysts could trigger multiple re-rating, yet near-term revenue flatness keeps valuation anchors low.
Risk assessment is tempered by recent insider activity, with $100,344 in net buying over the last 90 days suggesting management confidence despite stagnant top-line growth. While the Fama-French alpha data point was not provided to assess style exposure, the combination of high margins and low valuation implies a value tilt that may underperform during growth-led market regimes but offer defensive characteristics when volatility spikes. The investor must weigh whether the 0.9% revenue trajectory represents a cyclical trough or a structural limitation before concluding on the risk-reward profile of this deep-value opportunity.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Insider Activity (Last 90 Days)
Open-market buys vs sells by company insiders. Source: yfinance.
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like XHE or VBR, the fund manager is mechanically forced to buy or sell SOLV shares regardless of SOLV's individual fundamentals. We estimate $1.3B of passive capital is structurally linked to SOLV through 8 tracked ETFs. Index rebalances and ETF creation/redemption cycles can create noticeable volume spikes unrelated to company news.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in SOLV to visualize passive redemption contagion across ETFs and collateral stocks.
If SOLV (SOLV) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies ELI LILLY + CO (LLY) as the most exposed collateral stock, sharing 2 ETFs with SOLV. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 25 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
SOLV Ownership Dynamics
ETFs with Highest SOLV Exposure
Float lock-up computed from 25 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
SOLV Capital Efficiency
How efficiently does SOLV convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
SOLV converts -0% of its EBITDA into free cash flow, negative FCF conversion — the company is consuming cash faster than it generates EBITDA, which is unsustainable long-term. The 100% reinvestment rate signals aggressive capacity expansion. The positive ROIC-WACC spread of 7.7% confirms that reinvested capital creates shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-13 | 24,305 | $75.10 | $1.8M |
| 2026-05-07 | 49 | $70.99 | $3,478.51 |
| 2026-05-04 | 1,524 | $66.63 | $101,544.12 |
| 2026-04-30 | 67 | $66.49 | $4,454.83 |
| 2026-04-29 | 25,227 | $67.51 | $1.7M |
| 2026-04-24 | 42,620 | $68.96 | $2.9M |
| 2026-04-23 | 11,642 | $69.11 | $804,578.62 |
| 2026-04-21 | 34,403 | $70.04 | $2.4M |
| 2026-04-20 | 318 | $70.48 | $22,412.64 |
| 2026-04-15 | 173 | $69.02 | $11,940.46 |
| 2026-04-10 | 151 | $66.18 | $9,993.18 |
| 2026-04-09 | 151 | $65.25 | $9,852.75 |
| 2026-04-06 | 1 | $63.57 | $63.57 |
| 2026-04-01 | 251 | $65.30 | $16,390.3 |
| 2026-03-31 | 336 | $63.45 | $21,319.2 |
| 2026-03-27 | 137 | $64.71 | $8,865.27 |
| 2026-03-26 | 194 | $64.64 | $12,540.16 |
| 2026-03-25 | 15 | $64.03 | $960.45 |
| 2026-03-18 | 27 | $68.67 | $1,854.09 |
| 2026-03-17 | 1,122 | $67.14 | $75,331.08 |
| 2026-03-11 | 288 | $67.60 | $19,468.8 |
| 2026-03-04 | 5 | $70.81 | $354.05 |
| 2026-02-17 | 21,263 | $75.55 | $1.6M |
| 2026-02-11 | 1,514 | $80.46 | $121,816.44 |
| 2026-02-10 | 410 | $78.07 | $32,008.7 |
| 2026-02-06 | 549 | $76.98 | $42,262.02 |
| 2026-02-05 | 1,475 | $76.49 | $112,822.75 |
| 2026-01-28 | 522 | $77.61 | $40,512.42 |
| 2026-01-23 | 151 | $80.26 | $12,119.26 |
| 2026-01-20 | 58 | $79.48 | $4,609.84 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare SOLV to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.